The biopharmaceutical company Amgen has started the largest clinical trial to date of patients with stage five chronic kidney disease. The late-stage trial focuses on Amgen’s Sensipar/Mimpara, enrolling about 3,800 patients at 500 sites worldwide. Amgen is based in Thousand Oaks.